Acrivon Therapeutics, Inc. (ACRV) stock
ACRVNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.43−0.03 (-2.05%)
Close on Nov 17, 2026Market cap $61.28MP/E –Yield –
Acrivon Therapeutics EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
No ev/ebitda figures for Acrivon Therapeutics
Acrivon Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?